<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592667</url>
  </required_header>
  <id_info>
    <org_study_id>DAPA on VBP-AASI Hypertension</org_study_id>
    <nct_id>NCT03592667</nct_id>
  </id_info>
  <brief_title>Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension</brief_title>
  <official_title>Effect of Dapagliflozin on the Blood Pressure Variability and the Ambulatory Arterial Stiffness Index in Individuals With Stage I Hypertension Without Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of arterial hypertension has remained the same in the last 5 years, however,&#xD;
      almost 50% of the population continues without an adequate adjustment according to the&#xD;
      National Health Survey of the Midway 2016.&#xD;
&#xD;
      It has been shown that the variability of blood pressure (VBP) during 24 h and visit-visit is&#xD;
      associated with cardiovascular diseases (CVD) over the effect of blood pressure (BP) itself.&#xD;
      On the other hand, arterial stiffness is well known as an independent factor of CVD risk and&#xD;
      for its evaluation the ambulatory arterial stiffness index (AASI) has been proposed. AASI and&#xD;
      the VPA obtained through an evaluation by ambulatory BP monitoring (ABPM) individual of 24 h.&#xD;
&#xD;
      Dapagliflozin is an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) for the&#xD;
      treatment of diabetes mellitus type 2 (DM2) that promotes natriuresis and osmotic diuresis,&#xD;
      which produces a decrease in plasma volume and a decrease in BP.&#xD;
&#xD;
      The aim of ths study is to evaluate the effect of dapagliflozin on VBP and AASI in&#xD;
      individuals with stage I hypertension whitout DM2.&#xD;
&#xD;
      The investigators hypothesis is that the administration of dapagliflozin decreases the VBP&#xD;
      and AASI in individuals with stage I hypertension whitout DM2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial in 20 patients with a diagnosis&#xD;
      of stage I hypertension without DM2.&#xD;
&#xD;
      They will be assigned randomly two groups of 10 patients each to receive 10 mg of&#xD;
      Dapagliflozin (Forxiga, Astra Zeneca) or placebo, one per day before breakfast during 12&#xD;
      weeks.&#xD;
&#xD;
      There will be calculated indices of VBP: 24 h, daytime and night-time standard deviation&#xD;
      (SD), coefficient of variation (CV), 24 h weighted SD, Day-to-nigth BP changes and average&#xD;
      real variability (AVR). On the other hand, AASI will be calculated with a linear regression.&#xD;
&#xD;
      This protocol it's already approved by the local ethics committee and written informed&#xD;
      consent it's going to be obtained from all volunteers.&#xD;
&#xD;
      Statistical analysis will be presented through measures of central tendency and dispersion,&#xD;
      average and deviation standard for quantitative variables; frequencies and percentages for&#xD;
      variable qualitative. Qualitative variables will be analyzed by X2 o exact fisher test, will&#xD;
      be used for differences inter-group. Mann-Whitney U Test and Wilcoxon Test for the&#xD;
      within-groups differences. It will be considered statistical significance p ≤0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Indices of blood pressure: 24 h, daytime and night-time SD and CV, 24 h weighted SD, day-to-nigth BP changes and ARV</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Blood pressure variability will be evaluated with ambulatory blood pressure monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory arterial stiffness index</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Arterial stiffness will be evaluated with ambulatory blood pressure monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse Pressure of 24 h</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Will be evaluated with ambulatory blood pressure monitoring, systolic BP minus diastolic BP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure of 24 h, daytime and nigth-time</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Will be evaluated with ambulatory blood pressure monitoring, systolic BP minus diastolic BP/3, plus diastolic BP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate of 24 h, daytime and nigth-time</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Will be evaluated with ambulatory blood pressure monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertensive load daytime and nigth-time</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Will be evaluated with ambulatory blood pressure monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White coat hypertension</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>will be evaluated with ambulatory blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The fasting glucose levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Triglycerides levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein (c-HDL) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>c-HDL levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Creatinine levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Uric acid levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>The body weight will be measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Body Mas Index will be calculated at baseline, week 4, week 8 and week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Waist circumference will be evaluated with the method proposed by ISAK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Glomerular filtration rate will be calculated at baseline and week 12 with the Cockcroft-Gault formula and the entered values reflect the Glomerular filtration rate at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, one per day before breakfast during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10 mg, one per day before breakfast during 12 weeks.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Cap</intervention_name>
    <description>One per day before breakfast during 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  Patients both sexes, age between 30 and 60 years&#xD;
&#xD;
          -  Diagnosis of stage I hypertension according ACC/AHA (American college of&#xD;
             cardiology/American heart association) blood pressure between 130-139/ 80-89 mmHg.&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 100 mg/dl&#xD;
&#xD;
          -  BMI &gt;35 kg/m2&#xD;
&#xD;
          -  Glomerular filtration rate &gt; 60ml/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Hypersensibility to ingredients of intervention&#xD;
&#xD;
          -  Physical impossibility for taking pills&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart, thyroid or cardiovascular diseased&#xD;
&#xD;
          -  Previous treatment for hypertension or depression&#xD;
&#xD;
          -  Triglycerides ≥ 400 mg/dl&#xD;
&#xD;
          -  Total cholesterol ≥ 240 mg/dl&#xD;
&#xD;
          -  Worker per shift night&#xD;
&#xD;
          -  Arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <phone>+52-10-58-52-00</phone>
    <phone_ext>34212</phone_ext>
    <email>uiec@prodigy.net.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LIZET YADIRA ROSALES, PhD</last_name>
    <phone>+52-10-58-52-00</phone>
    <phone_ext>34212</phone_ext>
    <email>lizet.rosales@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANUEL GONZALEZ, PhD</last_name>
      <phone>+52-10-58-52-00</phone>
      <phone_ext>34212</phone_ext>
      <email>uiec@prodigy.net.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Professor investigator titular C</investigator_title>
  </responsible_party>
  <keyword>Stage I Hypertension</keyword>
  <keyword>Without type 2 diabetes mellitus</keyword>
  <keyword>Variability of blood pressure</keyword>
  <keyword>Ambulatory arterial stiffness index</keyword>
  <keyword>Dapagliflozin</keyword>
  <keyword>ABPM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

